G Mancia

Summary

Affiliation: University of Milano-Bicocca
Country: Italy

Publications

  1. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-51 pubmed publisher
    ..Interindividual BP variability during treatment shows marked quantitative differences with intraindividual BP variability questioning whether its use can accurately reflect individual BP variations from one visit to another. ..
  2. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126:569-78 pubmed publisher
    ..Thus, when BP is modestly elevated, inconsistency of BP control between visits plays a less important prognostic role than long-term average BP levels. ..
  3. Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219 pubmed publisher
  4. request reprint
    Mancia G, Cannon C, Tikkanen I, Zeller C, Ley L, Woerle H, et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension. 2016;68:1355-1364 pubmed
    ..URL: https://clinicaltrials.gov. Unique identifier: NCT01370005. ..
  5. Mancia G, Rosei E, Ambrosioni E, Avino F, Carolei A, Daccò M, et al. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). J Hypertens. 2011;29:309-18 pubmed publisher
    ....
  6. Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment?. Eur J Intern Med. 2017;: pubmed publisher
    ..At present, it is advisable to treat RH with the addition of an anti-aldosterone agent. If BP control is not achieved or serious side effects become manifest RDN may then be considered. ..
  7. Mancia G, Schumacher H, Bohm M, Redon J, Schmieder R, Verdecchia P, et al. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. Hypertension. 2017;70:938-948 pubmed publisher
    ..Prediction improved by their combined use, which may thus offer a more precise estimate of the protective effect of treatment. URL: http//www.clinicaltrial.gov. Unique identifier: NCT153.101. ..

Detail Information

Publications7

  1. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-51 pubmed publisher
    ..Interindividual BP variability during treatment shows marked quantitative differences with intraindividual BP variability questioning whether its use can accurately reflect individual BP variations from one visit to another. ..
  2. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126:569-78 pubmed publisher
    ..Thus, when BP is modestly elevated, inconsistency of BP control between visits plays a less important prognostic role than long-term average BP levels. ..
  3. Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219 pubmed publisher
  4. request reprint
    Mancia G, Cannon C, Tikkanen I, Zeller C, Ley L, Woerle H, et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension. 2016;68:1355-1364 pubmed
    ..URL: https://clinicaltrials.gov. Unique identifier: NCT01370005. ..
  5. Mancia G, Rosei E, Ambrosioni E, Avino F, Carolei A, Daccò M, et al. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). J Hypertens. 2011;29:309-18 pubmed publisher
    ....
  6. Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment?. Eur J Intern Med. 2017;: pubmed publisher
    ..At present, it is advisable to treat RH with the addition of an anti-aldosterone agent. If BP control is not achieved or serious side effects become manifest RDN may then be considered. ..
  7. Mancia G, Schumacher H, Bohm M, Redon J, Schmieder R, Verdecchia P, et al. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. Hypertension. 2017;70:938-948 pubmed publisher
    ..Prediction improved by their combined use, which may thus offer a more precise estimate of the protective effect of treatment. URL: http//www.clinicaltrial.gov. Unique identifier: NCT153.101. ..